Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: Results of a randomized, placebo-controlled, double-blind study

Journal of Sexual Medicine

Volumn 9, Issue 1, 2012, Pages 271-281

  Egerdie, Russell Blair ^a   Auerbach, Stephen ^b   Roehrborn, Claus G ^c   Costa, Pierre ^d   Garza, Martin Sanchez ^e   Esler, Anne L ^f   Wong, David G ^g   Secrest, Roberta J ^g  

^a Urology Associates Urologic Medical Research   (Canada)

^b California Professional Research   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d DEPARTMENT OF NEUROLOGY   (France)

^e Fundacion Mexicana para la Salud AC   (Mexico)

^f SYNEOS HEALTH   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Benign Prostatic Hyperplasia; Phosphodiesterase Type 5 Inhibitors; Tadalafil

Indexed keywords

PLACEBO; TADALAFIL;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; GENERAL CONDITION IMPROVEMENT; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84855385961     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02504.x     Document Type: Article

References (24)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-49.
2. AUA BPH Guideline Panel. American Urological Association guideline: Management of Benign Prostatic Hyperplasia (BPH). 2010. Available at: Revised 2010. (accessed May 4, 2011).
3. Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
4. McVary KT, McKenna KE. The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. Curr Urol Rep 2004;5:251-7.
5. AUA Erectile Dysfunction Guideline Update Panel. American Urological Association guideline: Management of Erectile Dysfunction. Published 2005/Updated 2006. (accessed May 15, 2011).
6. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; 2010.
7. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006;66:287-301.
8. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-7.
9. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den EG. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-7.
10. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53:1236-44.
11. Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369, 003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010;106:674-80.
12. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. J Urol 2008;180:1228-34.
13. Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005;7(9 suppl):S3-14.
14. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98-101.
15. Dmitrienko A, Tamhane AC, Wiens BL. General multistage gatekeeping procedures. Biom J 2008;50:667-77.
16. Xu H, Nuamah I, Liu J, Lim P, Sampson A. A Dunnett-Bonferroni-based parallel gatekeeping procedure for dose-response clinical trials with multiple endpoints. Pharm Stat 2009;8:301-16.
17. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: How much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-4.
18. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009;56:727-35.
19. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP III, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US. Int J Impot Res 2007;19:95-103.
20. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A, Shen W, Whitaker JS. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006;50:351-9.
21. Broderick GA, Brock GB, Roehrborn CG, Watts SD, Elion-Mboussa A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-8.
22. Roehrborn CG, Kaminetsky JC, Auerbach SM, Montelongo RM, Elion-Mboussa A, Viktrup L. Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-7.
23. Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: A randomized, placebo controlled 12-week clinical trial. J Urol 2010;183:1092-7.
24. Donatucci CF, Brock GB, Goldfischer ER, Pommerville PJ, Elion-Mboussa A, Kissel JD, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A 1-year, open-label extension study. BJU Int 2011;107:1110-6.